![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 7 of 7. This is the beginning of the thread.
Posted by rovers95 on June 20, 2010, at 17:01:35
Below is a link regarding AstraZeneca's TC-5214, which is being proposed for release in 2013 (all being well) as an augmentor for antidepressants when patients fail the initial trial, it has shown promising results in this respect so far and as someone who subscribes to the cholinergic theory of depression i believe/hope it may benefit myself and many others.
there's plenty of stuff out there on this drug, such as.
http://www.medicalnewstoday.com/articles/157831.php
Unlike scopolamine, which i responded to briefly but then went into cholinergic overdrive since i believe that TC-5214 is a non-competitive antagonist of nicotinic receptors. Will this mechanism of antagonism prevent the up-regulation of nicotinic receptors that hinders long term success with current nicotinic antagonists?
Also, i don't really understand what it takes to get a new drug onto the market so is anyone able to shed any light on the probability of this drug making it into production?
thanks
rover
Posted by SLS on June 20, 2010, at 17:24:03
In reply to TC-5214...future hope for depression??, posted by rovers95 on June 20, 2010, at 17:01:35
Thanks for posting this.
- Scott
Posted by Bob on June 22, 2010, at 2:30:30
In reply to TC-5214...future hope for depression??, posted by rovers95 on June 20, 2010, at 17:01:35
> Below is a link regarding AstraZeneca's TC-5214, which is being proposed for release in 2013 (all being well) as an augmentor for antidepressants when patients fail the initial trial, it has shown promising results in this respect so far and as someone who subscribes to the cholinergic theory of depression i believe/hope it may benefit myself and many others.
>
> http://www.news-medical.net/news/20100420/AstraZenecaTargacepts-TC-5214-for-treatment-resistant-depression-to-earn-Decision-Resources-gold-standard-status.aspx
>
> there's plenty of stuff out there on this drug, such as.
>
> http://www.medicalnewstoday.com/articles/157831.php
>
> Unlike scopolamine, which i responded to briefly but then went into cholinergic overdrive since i believe that TC-5214 is a non-competitive antagonist of nicotinic receptors. Will this mechanism of antagonism prevent the up-regulation of nicotinic receptors that hinders long term success with current nicotinic antagonists?
>
> Also, i don't really understand what it takes to get a new drug onto the market so is anyone able to shed any light on the probability of this drug making it into production?
>
> thanks
>
> rover
>
I find this interesting since bupropion helped me greatly for a little while when I added it to citalopram. I often wonder whether it was the nicotinic receptor antagonist properties it is thought to have, since that was the one thing about the drug I can point to as uniquely different than most other ADs I've taken.Bob
Posted by rovers95 on June 22, 2010, at 22:03:05
In reply to Re: TC-5214...future hope for depression??, posted by Bob on June 22, 2010, at 2:30:30
Just wondering if anyone new the procedure for and/or the chances of TC-5214 getting to market. Am i right in inferring that te proposed release would be in 2013?
cheers
rover
Posted by linkadge on June 25, 2010, at 18:46:34
In reply to Re: TC-5214...chances of getting to market??, posted by rovers95 on June 22, 2010, at 22:03:05
Yeah, thanks for posting this. Zopiclone helps my depression more than other benzodiazapines or sedatives. Apparently it has some nicotinergic receptor antagonism.
Linkadge
Posted by Conundrum on June 27, 2010, at 16:01:30
In reply to Re: TC-5214...future hope for depression??, posted by Bob on June 22, 2010, at 2:30:30
Interesting. It's always good to have something new in the arsenal for depression. I wonder if any older drugs will be screened for activity at the nicotinergic receptors?
I wouldn't be surprised if a big part of Wellbutrin's effectiveness comes from it having nicotinergic blocking properties, since its actions actions as a dopamine-norepinephrine reuptake inhibitor are rather weak.
Posted by rovers95 on June 27, 2010, at 17:40:25
In reply to Re: TC-5214...chances of getting to market??, posted by linkadge on June 25, 2010, at 18:46:34
> Yeah, thanks for posting this. Zopiclone helps my depression more than other benzodiazapines or sedatives. Apparently it has some nicotinergic receptor antagonism.
>
> LinkadgeInteresting, so you take zopiclone for depression and not insomnia, what are the dosages you use?
rover
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.